Revolution Medicines(RVMD)

Search documents
Revolution Medicines Announces Publication Demonstrating Robust Anti-Tumor Activity of RAS(ON) Inhibitors in Preclinical Models of Refractory KRAS-Mutated Non-Small Cell Lung Cancer
GlobeNewswire News Room· 2024-07-11 16:00
Original research published in Cancer Discovery reveals a RAS(ON) multi-selective inhibitor exhibited robust anti-tumor activity alone or in combination with a RAS(ON) G12C-selective inhibitor in preclinical models of difficult-to-treat KRAS-mutated non-small cell lung cancer (NSCLC) REDWOOD CITY, Calif., July 11, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced the publ ...
Revolution Medicines (RVMD) Moves 11.0% Higher: Will This Strength Last?
ZACKS· 2024-07-10 11:01
The sudden soaring of the stock price can be attributed to the positive investor mindset regarding the progress in the development of Revolution's lead investigational candidate, RMC-6236. The company is currently evaluating RMC-6236 as a monotherapy as well as in combination with other agents in seprate early-stage studies across a variety of oncology indications. Revolution's clinical-stage pipeline also comprises two other early-stage candidates, being devolped for solid tumour indications. Earnings and ...
Revolution Medicines to Provide Update on RMC-6236 Pancreatic Ductal Adenocarcinoma Clinical Program on July 15, 2024
GlobeNewswire News Room· 2024-07-08 20:05
REDWOOD CITY, Calif., July 08, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that it will host an investor webcast to provide an update on its RMC-6236 pancreatic ductal adenocarcinoma (PDAC) clinical development program. Speakers will include members of Revolution Medicines' management team, along with Brian M. Wolpin, M.D., M.P.H., professor of medicine at Harvard M ...
Revolution Medicines to Provide Update on RMC-6236 Pancreatic Ductal Adenocarcinoma Clinical Program on July 15, 2024
Newsfilter· 2024-07-08 20:05
The webcast will take place at 8:00 a.m. Eastern Time on Monday, July 15, 2024. To access the live webcast, please visit the "Events & Presentations" page of Revolution Medicines' website at https://ir.revmed.com/events-and-presentations. Additionally, a replay of the webcast will be available on the "Events & Presentations" page of the Revolution Medicines website for at least 14 days following the event. About Revolution Medicines, Inc. REDWOOD CITY, Calif., July 08, 2024 (GLOBE NEWSWIRE) -- Revolution Me ...
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Revolution Medicines, Inc. (NASDAQ: RVMD)
Prnewswire· 2024-07-08 13:00
NEW YORK, July 8, 2024 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Revolution Medicines, Inc. (NASDAQ: RVMD) on behalf of the company's shareholders. The investigation seeks to determine whether Revolution Medicines's directors breached their fiduciary duties in connection with recent corporate actions. If you are a shareholder of Revolution Medicines, Inc. and are interested in obtaining additional information regarding your rights and options, free of charge, please visit us ...
Revolution Medicines(RVMD) - 2024 Q1 - Earnings Call Transcript
2024-05-09 01:11
Financial Data and Key Metrics Changes - The company ended Q1 2024 with $1.7 billion in cash and investments, down from $1.85 billion at the end of 2023, primarily due to net loss and a decrease in accounts payable and accrued liabilities [15][34] - R&D expenses for Q1 2024 were $118.0 million, compared to $68.9 million in Q1 2023, driven by clinical trial expenses [34] - The net loss for Q1 2024 was $116.0 million, or $0.70 per share, with a projected full-year GAAP net loss expected to be between $480 million and $520 million [35] Business Line Data and Key Metrics Changes - The company is focused on advancing RMC-6236 into pivotal monotherapy trials for major cancers driven by oncogenic RAS variants, with updates expected in the second half of the year [23][24] - RMC-6236 is being evaluated in combination studies for pancreatic and colorectal cancers, which are crucial for establishing first-line registrational paths [9][10] Market Data and Key Metrics Changes - The company anticipates that the first registrational studies for RMC-6236 will launch in the second half of the year, targeting advanced pancreatic cancer and non-small cell lung cancer [14][24] - The competitive landscape includes other KRAS G12C inhibitors, but the company believes that RMC-6236 will provide a treatment option for patients without G12C mutations [42][44] Company Strategy and Development Direction - The company has outlined three strategic priorities for 2024: advancing RMC-6236 into pivotal trials, expanding its reach beyond G12X mutations, and qualifying its first two RAS(ON) mutant-selective inhibitors [4][25][28] - The company is exploring combination therapies to enhance treatment efficacy and is committed to moving RMC-6236 into earlier lines of therapy [27][29] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the potential of RMC-6236, citing complete responses in some patients and the importance of targeting RAS addiction [26][32] - The company is well-capitalized and focused on delivering key data to advance its clinical programs, with a strong emphasis on safety and efficacy in combination therapies [36][37] Other Important Information - The company presented data at the AACR Annual Meeting, highlighting the potential of RMC-6236 across various RAS genotypes and tumor types [25][80] - Management emphasized the importance of establishing safety profiles for combination therapies before moving forward with clinical development [106][107] Q&A Session Summary Question: What questions are still being addressed for the pancreatic cancer study design? - The company needs to reach an agreement with the FDA on dosing and trial design, which are expected to be resolved in the first half of the year [37] Question: Will the first-line study wait for second-line trial results? - The company is evaluating both monotherapy and combination options for first-line treatment but has not made a definitive decision yet [39] Question: How might the KRYSTAL 12 trial results impact the company's studies? - The company believes that the impact will be minimal for pancreatic cancer, as G12C represents a small subpopulation [42] Question: What is the expected timeline for initial data from the RMC-6236 and pembrolizumab combination? - Initial safety data will likely not be from first-line patients, but the study is designed to enable a first-line strategy [46][51] Question: What is the company's approach to business development? - The company is committed to U.S. operations and plans to commercialize its compounds independently, while seeking partners for international markets [117][124]
Revolution Medicines(RVMD) - 2024 Q1 - Quarterly Report
2024-05-08 20:11
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___ to ___ Commission File Number: 001-39219 Revolution Medicines, Inc. (Exact Name of Registrant as Specified in its Charter) | Delaware | 47-2029180 | | --- | ...
Revolution Medicines(RVMD) - 2024 Q1 - Quarterly Results
2024-05-08 20:05
Exhibit 99.1 Revolution Medicines Reports First Quarter 2024 Financial Results and Update on Corporate Progress Revolution Medicines to hold webcast today at 4:30 p.m. Eastern Time REDWOOD CITY, Calif., May 8, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced its financial results for the quarter ended March 31, 2024, and provided an update on corporate progress. The comp ...
Revolution Medicines(RVMD) - 2023 Q4 - Earnings Call Transcript
2024-02-27 03:45
Financial Data and Key Metrics Changes - The company ended 2023 with $1.85 billion in cash and investments, expected to fund operations into 2027 [18] - Collaboration revenue for Q4 2023 was $0.7 million, down from $15.3 million in the prior year quarter, and full-year revenue was $11.6 million compared to $35.4 million in the previous year [19] - Total operating expenses for Q4 2023 increased to $180.7 million, driven by R&D expenses totaling $148.5 million, while full-year operating expenses reached $498.8 million [26] - The net loss for Q4 2023 was $161.5 million, or $1.14 per share, and for the full year, the net loss was $436.4 million, or $3.86 per share [27][28] Business Line Data and Key Metrics Changes - The company reported favorable trends in aggregate objective response rates (ORR) for RMC-6236 in non-small cell lung cancer, reaching the low to mid-40s range, and in pancreatic ductal adenocarcinoma, trending into the mid-20s [12][13] - RMC-9805, an oral G12D selective inhibitor, has confirmed oral bioavailability in patients, with no dose-limiting toxicities reported [16][17] Market Data and Key Metrics Changes - The company is expanding the reach of RMC-6236 to include patients with tumors harboring RAS mutations beyond G12X, including G13X and Q61X mutations, and studying it in various tumor types beyond lung and pancreatic cancer [14] Company Strategy and Development Direction - The company has three strategic priorities for 2024: advancing RMC-6236 into pivotal trials, expanding its reach, and qualifying RMC-6291 and RMC-9805 for late-stage development [11][15] - The company aims to propel RMC-6236 into its first pivotal trial against standard-of-care chemotherapy for RAS-mutated non-small cell lung cancer and pancreatic ductal adenocarcinoma [11] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the strong balance sheet and pipeline, emphasizing the commitment to developing targeted therapies for patients with RAS-addicted cancers [24][29] - The company anticipates disclosing initial clinical data for RMC-6236 and its combinations in the second half of 2024, with a focus on safety and efficacy [15][40] Other Important Information - The company reported that the increase in expected GAAP net loss for 2024 is due to increased expenses associated with ongoing clinical development programs [28] - Management highlighted the importance of establishing a safety profile for combinations with checkpoint inhibitors before moving into first-line treatment settings [33] Q&A Session Summary Question: What data is needed to move combinations with pembrolizumab into pivotal development? - Management is primarily looking to validate safety, particularly concerning hepatotoxicity signals [33] Question: How much more data is needed to support initiation of Phase 3 trials for RMC-6236? - A mature progression-free survival (PFS) assessment is required, along with FDA input [39] Question: What are the gating steps for starting a frontline pancreatic combination study? - The company is exploring combinations with standard regimens like modified FOLFIRINOX and gem-ABRAXANE, focusing on response rates and survival benefits [54] Question: What is the primary endpoint for the Phase 3 trial in second-line pancreatic cancer? - The current thinking is to evaluate both PFS and overall survival (OS) as endpoints [64] Question: What indications should be expected for data updates from expansion cohorts? - Data will be provided for various RAS genotypes and tumor types, including colorectal cancer, in the second half of the year [72] Question: How does the company view partnering opportunities? - The company aims to build its own franchise in the U.S. but is open to partnerships outside the U.S. for commercialization [100][102]
Revolution Medicines(RVMD) - 2023 Q4 - Annual Report
2024-02-26 21:08
UNITED STATES SECURITIES AND EXCHANGE COMMISSION ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Washington, D.C. 20549 For the fiscal year ended December 31, 2023 OR FORM 10-K (Mark One) Revolution Medicines, Inc. (Exact name of Registrant as specified in its Charter) | Delaware | 47-2029180 | | --- | --- | | (State or other jurisdiction of | (I.R.S. Employer | | incorporation or organization) | Identification No.) | | 700 Saginaw Drive | | | Redwood City, CA | 94063 ...